FDA向重庆千璨科技签发警告信(参考号320-27-14),涉拒绝提供704(a)(4)记录并列入进口警报66-79
FDA警告信:重庆千璨科技有限公司
FDA向重庆千璨科技有限公司签发警告信(MARCS-CMS 736416,参考号320-27-14),认定其拒绝提供FD&C法案第704(a)(4)条要求的记录,并于2026年8月26日将该企业所有拟进口至美国的药品和药品制剂列入进口警报66-79。
近日,FDA向重庆千璨科技有限公司(FDA文件中写作 Chongqing Qiancan Technology Co., Ltd.,下称CQT)签发警告信(MARCS-CMS 736416,参考号320-27-14)。
事情从进口记录开始。FDA发现有多批申报CQT为生产商、拟进入美国用于处方配制的原料药,于是按FD&C法案第704(a)(4)条,向企业注册档案里的联系邮箱发出记录索取要求。接下来的时间线是这封信里最刺眼的部分:2026年6月17日发出要求;6月29日企业注销注册、停用药品列名;6月30日回信称无法满足FDA要求;7月13日又重新注册。所要求的记录始终没有提供,而企业生产的原料药已经进入美国市场,且仍在有效期内。
FDA据此认定,拒绝允许查阅或复制第704(a)条要求的记录,属于FD&C法案第301(e)条下的禁止行为;并已于2026年8月26日将CQT所有拟进口至美国的药品和药品制剂列入进口警报66-79。
翻译如下:
To Wenjuan Li:
致 Wenjuan Li:
This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.
本警告信告知你司:FDA在审查你司设施提交的记录时发现了一项重大违规,并给予你司说明和处理的机会。本信并非违规的完整清单。确保你司符合联邦法律(包括FDA法规)的全部要求,是你司的责任。未充分处理任何违规,可能导致FDA在不另行通知的情况下采取监管行动。
Your facility, Chongqing Qiancan Technology Co., Ltd. (hereafter CQT), FDA Establishment Identifier (FEI) # 3040333997 at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).
你司设施——重庆千璨科技有限公司(下称CQT),FDA企业识别号(FEI)3040333997,地址为重庆市长寿区渡舟街道商贸中路505号附8号9-13——在美国FDA注册为原料药(API)生产商。
A review of import records showed multiple shipments of API intended for prescription compounding into the U.S., which declared CQT as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.
对进口记录的审查显示,有多批拟进入美国、用于处方配制的原料药,申报CQT为药品生产商。FDA依据《联邦食品、药品和化妆品法案》(FD&C法案)第704(a)(4)条(21 U.S.C. 374(a)(4)),向你司注册档案中提供的联系邮箱发出索取记录和其他信息的要求。你司拒绝提供这些依法要求的记录。
It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as having been manufactured at your facility.
拒绝允许查阅或复制第704(a)条要求的任何记录,属于FD&C法案第301(e)条(21 U.S.C. 331(e))下的禁止行为。由于你司未回应第704(a)(4)条的记录要求及相关沟通尝试,我方无法了解你司设施所列药品的质量保证水平。
Refusal to Provide Records
拒绝提供记录
On June 17, 2026, FDA sent an electronic records request to the contact email address on file in your registration. Your firm de-registered and discontinued your drug listing on June 29, 2026, one day prior to your reply on June 30, 2026, in which you stated that your firm was unable to meet FDA requirements. The requested records were never provided despite APIs manufactured by your firm being imported to the U.S. market and still being within expiry.
2026年6月17日,FDA向你司注册档案中的联系邮箱发送了电子记录要求。你司于2026年6月29日注销注册并停用药品列名,比你司6月30日的回复早一天;在该回复中你司称无法满足FDA要求。尽管你司生产的原料药已进入美国市场、且仍在有效期内,所要求的记录始终未提供。
Notably, your firm re-registered on July 13, 2026.
值得注意的是,你司于2026年7月13日重新注册。
It is your responsibility to ensure the drugs you manufacture meet U.S. standards prior to distributing them into the U.S. supply chain.
在将所生产药品投入美国供应链之前,确保其符合美国标准,是你司的责任。
FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 26, 2026.
FDA已于2026年8月26日将你司所有拟进口至美国的药品和药品制剂列入进口警报66-79。
Conclusion
结论
The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.
本信所列违规并非你司设施全部违规的完整清单。
Until FDA is able to confirm your compliance with Current Good Manufacturing Practice and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at CQT, located at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing coming into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).
在FDA能够确认你司符合现行药品生产质量管理规范(CGMP)及其他适用要求之前,我方可能暂缓批准任何将你司列为药品生产商的新申请或补充申请。此外,CQT(地址:重庆市长寿区渡舟街道商贸中路505号附8号9-13)生产并进入美国的物品,如疑似掺假或标签不当,可依据FD&C法案第801(a)(3)条(21 U.S.C. 381(a)(3))被扣留或拒绝入境。
In response to this letter, you may submit a request to schedule an FDA inspection.
作为对本信的回复,你司可提交安排FDA检查的申请。
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3040333997 and ATTN: Marva Taylor in the subject line of the email.
请在收到本信后十五(15)个工作日内将书面回复发送至 CDER-OC-OMQ-Communications@fda.hhs.gov。请在邮件主题行注明 FEI 3040333997 及 ATTN: Marva Taylor。
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
如果你司认为有信息可证明你司产品未违反FD&C法案和FDA法规,请一并提供供我方考虑。
FDA posts warning letters to www.FDA.gov.
FDA将警告信公布于 www.FDA.gov。
Sincerely, /S/ Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
此致。签名:/S/ Francis Godwin(弗朗西斯·戈德温),主任,生产质量办公室,合规办公室,药品评价与研究中心,美国FDA
cc: U.S. agent
抄送:美国代理人
来源:制药经理人 · mp.weixin.qq.com